Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colonic Neoplasms 23Rectal Neoplasms 22Squamous Cell Carcinoma of Head and Neck 17Colorectal Neoplasms 13Salivary Gland Neoplasms 7Tongue Neoplasms 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Mouth Neoplasms 4Laryngeal Neoplasms 4Neoplasm Metastasis 3Lymphoid Interstitial Pneumonia 3Hypopharyngeal Neoplasms 3Carcinoma 3Oropharyngeal Neoplasms 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Squamous Cell 2Adenocarcinoma of Lung 2Stomach Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Pleural Effusion, Malignant 1Pharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Locally Recurrent Skin Squamous Cell Carcinoma 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Locally Recurrent Skin Squamous Cell Carcinoma × Cetuximab × Clear all
NCT07042295 2026-05-27

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡